As the life sciences industry prepares to gather at INTERPHEX in New York City (April 21-23, 2026), Ascendia Pharmaceutical Solutions will once again be represented by one of its most experienced scientific voices, Shaukat Ali, PhD, FAAPS, Sr Director, Scientific Affairs & Technical Marketing. While Ascendia Pharmaceutical Solutions' presence at INTERPHEX has evolved over the years, its commitment to engaging with the broader pharmaceutical manufacturing and development ecosystem remains constant.
Dr. Ali brings a unique perspective shaped not only by his scientific leadership at Ascendia Pharmaceutical Solutions but also by his direct involvement in the past at INTERPHEX. Having previously participated in both roundtable discussions and podium presentations, including sessions focused on long-acting injectables, he has contributed to conversations that are actively shaping how the industry approaches complex formulation and delivery challenges.
INTERPHEX continues to stand apart as a venue where multiple segments of the pharmaceutical industry converge. From CDMOs and CROs to equipment manufacturers and service providers, the event offers a comprehensive view of how drug products are developed, manufactured, and scaled. For a company like Ascendia Pharmaceutical Solutions, whose work sits at the intersection of formulation science, drug delivery, and development strategy, and cGMP manufacturing of aseptic and non-aseptic products across all modalities, this environment is particularly valuable and well-suited.
Dr. Ali notes that one of the defining characteristics of INTERPHEX is its emphasis on innovation through equipment and process advancement. New technologies, from fill-finish systems to advanced coating and processing equipment, are introduced and demonstrated in real time. These innovations are not just incremental improvements and learnings; they often represent meaningful shifts in efficiency, scalability, and product quality.
One of the most important recent developments at INTERPHEX is its collaboration with the American Association of Pharmaceutical Scientists (AAPS). This mutual alliance has elevated the event beyond its historical focus on equipment and manufacturing by bringing a stronger scientific and technical dimension to the program.
According to Dr. Ali, this shift has significantly enhanced the overall value of the meeting. The integration of AAPS programming introduces deeper scientific discussions, expands the range of expert perspectives, and attracts a broader audience from across the pharmaceutical development lifecycle. The result is a more balanced event, where engineering, manufacturing, and science are equally represented.
Although Dr. Ali will not be presenting this year, his focus remains firmly on engagement. INTERPHEX provides an ideal setting to listen to emerging perspectives, evaluate new technologies, and identify opportunities for collaboration across the industry. For Ascendia Pharmaceutical Solutions, these interactions are critical, as they inform how the company continues to evolve its capabilities in formulation development, especially in areas of complex injectables and advanced drug delivery systems for unmet medical needs.
Beyond the technical discussions, the event also serves as a hub for relationship-building. With its location at the Jacob Javits Center in New York City, INTERPHEX offers accessibility and scale that few other meetings can match. The concentration of global companies, combined with the density of networking opportunities, makes it an ideal environment for forming new partnerships and strengthening existing ones beyond the convention.
For those attending INTERPHEX, Dr. Ali will be available to discuss how Ascendia Pharmaceutical Solutions is supporting pharmaceutical companies in overcoming formulation and development challenges. Whether the focus is on long-acting injectables, complex drug delivery systems, or broader development strategies, the conversation is grounded in both scientific rigor and practical experience.
As INTERPHEX continues to evolve into a more integrated and science-driven event, Ascendia Pharmaceutical Solutions' presence reflects its role within that ecosystem, bridging innovation, development, and execution in an increasingly complex pharmaceutical landscape.